Jiarui Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6864758/publications.pdf

Version: 2024-02-01

1039880 940416 22 296 9 16 citations h-index g-index papers 22 22 22 349 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Single-cell RNA sequencing reveals a pro-invasive cancer-associated fibroblast subgroup associated with poor clinical outcomes in patients with gastric cancer. Theranostics, 2022, 12, 620-638.	4.6	94
2	Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 1098.	1.3	29
3	Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092202.	1.4	29
4	Participation of Black US Residents in Clinical Trials of 24 Cardiovascular Drugs Granted FDA Approval, 2006-2020. JAMA Network Open, 2021, 4, e212640.	2.8	22
5	CA19-9 elevation as an indication to start salvage treatment in surveillance after pancreatic cancer resection. Pancreatology, 2019, 19, 302-306.	0.5	20
6	Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review. Frontiers in Oncology, 2020, 10, 602705.	1.3	20
7	Immune Checkpoint Markers in Neuroendocrine Carcinoma of the Digestive System. Frontiers in Oncology, 2020, 10, 132.	1.3	19
8	Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097535.	1.4	18
9	Multi-Modality Treatment for Patients With Metastatic Gastric Cancer: A Real-World Study in China. Frontiers in Oncology, 2019, 9, 1155.	1.3	13
10	Health status of middle-aged and older cancer survivors: a nationwide cross-sectional study from the China Health and Retirement Longitudinal Study (CHARLS). Annals of Translational Medicine, 2020, 8, 183-183.	0.7	8
11	Impact of corticosteroids use on efficacy of immune checkpoint inhibitors in cancer patients: A meta-analysis Journal of Clinical Oncology, 2020, 38, e15234-e15234.	0.8	7
12	Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep). European Journal of Cancer, 2022, 169, 1-9.	1.3	5
13	Influenza in hospitalised patients with malignancy: a propensity score matching analysis. ESMO Open, 2020, 5, e000968.	2.0	4
14	Genetically predicted telomere length and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 60, 103731.	0.9	4
15	Use of Participation to Prevalence Ratio for Evaluating the Representation Status of Women in Oncology Clinical Trials. JAMA Oncology, 2022, 8, 479.	3.4	3
16	Health digital technology in COVID-19 pandemic: experience from China. BMJ Innovations, 2020, 6, 259-261.	1.0	1
17	Analysis of PD-1/PD-L1 blockade biomarker and immune infiltrates in gastroenteropancreatic neuroendocrine carcinoma. Annals of Oncology, 2019, 30, v568.	0.6	О
18	Health status of middle-aged and older cancer survivors in China: Results from the China Health and Retirement Longitudinal Study (CHARLS). Annals of Oncology, 2019, 30, v676-v677.	0.6	0

#	Article	IF	CITATIONS
19	Study Characteristics and Risk of Bias of Clinical Trials Supporting FDA Approval of Cardiovascular Drugs, 2006–2020. Journal of General Internal Medicine, 2021, , 1.	1.3	0
20	Efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with different metastatic sites: A systematic review and meta-analysis Journal of Clinical Oncology, 2020, 38, e21684-e21684.	0.8	0
21	Neoadjuvant chemotherapy or chemoradiotherapy versus upfront surgery alone for resectable or borderline resectable pancreatic cancer. The Cochrane Library, 2021, 2021, .	1.5	0
22	Influenza in hospitalized cancer patients: A propensity score matching analysis Journal of Clinical Oncology, 2020, 38, 170-170.	0.8	0